Our Product Pipeline
We strive to provide the highest-quality reagents in support of infectious disease research. Some of the highlights of our current pipeline are shown below, but if you can’t see what you are interested in please contact us to find out if we might already have it in development. If we don’t have what you need we may be able to develop it for you!
Our antigen pipeline
Our antigen pipeline reflects our specialism in the manufacture of infectious disease antigens to ensure retention of their native configuration. From initial research through to production scale-up we are focused on providing antigens which deliver real improvements to the sensitivity and specificity of serology based IVD’s, serve as effective immunogens and offer vital support in vaccine research. We specialise in preparing recombinant proteins in our HEK293 based mammalian cell expression system, and seek to avoid the use of bacterial expression systems such as E. coli which often fail to give sufficient representation of the true native state (unless the protein of interest is not glycosylated in the native state).
Our current R&D pipeline includes:
- Hepatitis E proteins
- St. Louis Encephalitis NS1 protein
- Recombinant Rubella proteins
- Hantavirus proteins
- Respiratory syncytial virus (RSV) proteins
- Schmallenberg virus proteins
If any of these antigens are of interest, please get in touch to be included in our beta testing, and to be first to partner using our unique antigens
Our antibody pipeline
Our current antibody pipeline includes the following targets:-
- Nipah virus
- Crimean Congo Hemorraghic Fever Virus
- Lassa Fever virus
- Alphaviruses (specific antibodies for Chikungunya, Mayaro and O’nyong’nyong viruses).
If you would like to be among the first to test these reagents do let us know, and we can keep you up to date on their development.